Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IMIPENEM Cause Chronic obstructive pulmonary disease? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Chronic obstructive pulmonary disease have been filed in association with IMIPENEM. This represents 0.4% of all adverse event reports for IMIPENEM.

7
Reports of Chronic obstructive pulmonary disease with IMIPENEM
0.4%
of all IMIPENEM reports
4
Deaths
4
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From IMIPENEM?

Of the 7 reports, 4 (57.1%) resulted in death, 4 (57.1%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IMIPENEM. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does IMIPENEM Cause?

Drug ineffective (351) Off label use (202) Condition aggravated (138) Vomiting (137) Drug resistance (117) Nausea (111) Dyspnoea (97) Diarrhoea (90) Pyrexia (90) Product use in unapproved indication (85)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which IMIPENEM Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

IMIPENEM vs IMIPRAMINE IMIPENEM vs IMIQUIMOD IMIPENEM vs IMITREX IMIPENEM vs IMMUNE GLOBULIN NOS IMIPENEM vs IMPLANON

Related Pages

IMIPENEM Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease IMIPENEM Demographics